Wrays head wins opposition to MacroGenics immunotherapy patent

Healthcare 2019-04-04 4:05 pm By Miklos Bolza | Sydney

Please login to bookmark

IP Australia has ordered biotech firm MacroGenics to amend its patent for a type of polypeptide used in treatments for cancer, autoimmune disorders and other diseases after a successful opposition from the chairman of intellectual property boutique Wrays.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au